29. The binding agent of any one of claims 1 to 28, wherein the binding agent has an N-terminal secretion signal and/or a C-terminal histidin epitope tag, preferable a six histidin epitope tag.

30. A recombinant nucleic acid which encodes a binding agent of any one of claims 1 to 29.

31. The recombinant nucleic acid of claim 30 which is in the form of a vector or in the form of RNA.

32. A host cell comprising a recombinant nucleic acid of claim 30 or 31.

33. The binding agent of any one of claims 1 to 29, the recombinant nucleic acid of claim 30 or 31 or the host cell of claim 32 for use in therapy, in particular for use in treating or preventing cancer.

34. A pharmaceutical composition comprising the binding agent of any one of claims 1 to 29, the recombinant nucleic acid of claim 30 or 31 or the host cell of claim 32.

35. Use of the binding agent of any one of claims 1 to 29, the recombinant nucleic acid of claim 30 or 31 or the host cell of claim 32 in the preparation of a medicament for use in ~~ther~~eating~~py~~ or preventing cancer.

~~36. The use of claim 35, wherein the medicament is for use in treating or preventing cancer.~~

3~~7~~6. The binding agent, the recombinant nucleic acid or the host cell of claim 33 or the ~~method~~use of claim 35, wherein cells of said cancer express a claudin to which said binding agent is capable of binding.

3~~8~~7. The binding agent, the recombinant nucleic acid, the host cell or the ~~method~~use of claim 3~~7~~6, wherein said claudin is CLDN18.2 and said cancer is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer

such as non small cell lung cancer (NSCLC), breast cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder and the metastasis thereof, a Krukenberg tumor, peritoneal metastasis and/or lymph node metastasis.

398. The binding agent, the recombinant nucleic acid, the host cell or the ~~method~~use of claim 376, wherein said claudin is CLDN6 and said cancer is selected from the group consisting of urinary bladder cancer, ovarian cancer, in particular ovarian adenocarcinoma and ovarian teratocarcinoma, lung cancer, including small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), in particular squamous cell lung carcinoma and adenocarcinoma, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, in particular basal cell carcinoma and squamous cell carcinoma, malignant melanoma, head and neck cancer, in particular malignant pleomorphic adenoma, sarcoma, in particular synovial sarcoma and carcinosarcoma, bile duct cancer, cancer of the urinary bladder, in particular transitional cell carcinoma and papillary carcinoma, kidney cancer, in particular renal cell carcinoma including clear cell renal cell carcinoma and papillary renal cell carcinoma, colon cancer, small bowel cancer, including cancer of the ileum, in particular small bowel adenocarcinoma and adenocarcinoma of the ileum, testicular embryonal carcinoma, placental choriocarcinoma, cervical cancer, testicular cancer, in particular testicular seminoma, testicular teratoma and embryonic testicular cancer, uterine cancer, germ cell tumors such as a teratocarcinoma or an embryonal carcinoma, in particular germ cell tumors of the testis, and the metastatic forms thereof.